HUMANIGEN: Gearing up for a potential launch of lenzilumab in COVID-19 | BUY | USD30 (+68%)
HUMANIGEN - BUY | USD30 (+68%)Gearing up for a potential launch of lenzilumab in COVID-19
Progressing towards EUA submission and potential launch
Phase III recruitment is on-track for Q1 readout
Increasing focus on therapeutics as countermeasures against COVID-19
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.